Introduction
============

Metabolic Syndrome and Adiponectin
----------------------------------

In pre-clinical and clinical conditions, the metabolic components of cardiovascular risk, such as obesity, insulin resistance and dyslipidemia, interact in a complex way, being associated with high cardiovascular morbidity and mortality^[@r01]-[@r11]^. Visceral obesity plays an increasingly relevant role as a cardiovascular risk factor. In fact, the adipose tissue is a storable energy source and an endocrine organ that secretes cytokines, which can contribute to the development of obesity-related diseases, such as diabetes mellitus (DM) and atherosclerosis. Matsuzawa et al^[@r12]^ have assessed the endocrine role of adipocytes and found an abundant expression of genes related to the synthesis of several bioactive substances, such as adiponectin (Arcp30, AdipoQ, apM1 or GBP28), a protein similar to collagen and identified as an adipocyte-specific cytokine.

Adiponectin is abundantly expressed in healthy individuals, has antithrombotic, antiatherogenic and anti inflammatory properties, and is downregulated in obese individuals. Similarly, adiponectin levels are reduced in male individuals, with type 2 DM, proinflammatory conditions, lipodystrophies, insulin resistance and cardiovascular disease. Inversely, serum adiponectin concentrations are elevated in women, non-obese individuals, with type 1 DM and in those undergoing treatment with peroxisome proliferator activated receptor gamma (PPARγ) agonists^[@r13]-[@r20]^. From the prognostic viewpoint, in healthy individuals, adiponectin has been inversely associated with cardiovascular risk, mainly in men, or directly associated with that risk, mainly in the elderly^[@r21]-[@r25]^. However, studies on chronic heart failure (HF) or documented cardiovascular disease (CVD) have identified hyperadiponectinemia as an independent predictor of mortality^[@r26]-[@r28]^. Similarly, Cavusoglu et al^[@r29]^ have identified a direct and independent association between adiponectin and the risk for acute myocardial infarction (AMI) and cardiovascular death in a cohort of men undergoing coronary angiography for the diagnostic investigation of chest pain. Those data suggest that adiponectin might play a different role in acute clinical scenarios. Thus, this study was aimed at assessing the association between serum adiponectin levels and the risk for cardiovascular events in patients with acute coronary syndromes (ACSs), and at establishing the correlations between adiponectin and metabolic, inflammatory and myocardial biomarkers.

Method
======

This study has two components: a) a cross-sectional and analytical component to determine the clinical characteristics and measures of serum biomarkers of patients with ACS on hospital admission; b) a cohort of ACS, prospectively included between 2008 and 2010, with clinical follow-up for the systematic and prospective collection of cardiovascular events. Based on the study by Cavusoglu et al^[@r29]^ on a subgroup of patients with ACS comprising 52.3% of a total of 325 patients and with all-cause mortality rate of 10.3% in two years of clinical follow-up, the calculation of the sample size was estimated as 112 patients, with significance of α = 0.05 and 1 − β = 0.80. It is worth noting that, due to the lack of studies about adiponectin in patients with ACSs in the Brazilian population up to the time of the elaboration of this dissertation project, and, thus, scarcity of data on the variability of that biomarker measurements, the possibility of inadequate estimation was considered. This study included patients of both sexes, over the age of 18 years, who underwent blood collection within the first 24 hours from ischemic symptom onset and who provided written informed consent, in the emergency and coronary units of the Instituto Dante Pazzanese de Cardiologia, in the city of São Paulo. Patients with the following characteristics were excluded: infectious, inflammatory and neoplastic diseases; end-stage kidney or liver disease; significant heart valve disease or heart valve disease precipitating the clinical findings; percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) in the preceding 30 days; previous and current use of insulin (patients with type 1 DM and those with type 2 DM requiring insulin); and use of oral antidiabetic drugs of the thiazolidinedione group. The following parameters were assessed: adiponectin; leptin; fasting glucose; insulin; Homeostasis Model Assessment (HOMA) index; glycated hemoglobin (HbA1c); total cholesterol, LDL- and HDL cholesterol; triglycerides; ultrasensitive C-reactive protein (us-CRP); leukocytes; fibrinogen; platelets; cardiac troponin I (TnI); CKMB mass; B-type natriuretic peptide (BNP); and demographic (age, sex, ethnicity), anthropometric (weight, body mass index and waist circumference) and angiographic (extension/severity of coronary artery disease \[CAD\] in patients undergoing coronary angiography) variables. Venous blood samples (10 mL) were collected in the morning following a 12-hour nocturnal fasting. Insulin resistance was expressed as the HOMA index calculated by using the formula \[product of glucose (mg/dL) by insulin (µUI / mL), divided by the constant 405\]^[@r30],[@r31]^. Adiponectin and leptin were measured by use of ELISA assay. The kits for measuring adiponectin were Human Adiponectin ELISA Kit 96-Well Plate (Cat. \# EZHADP-61K), manufactured by Millipore, United States. The kits for measuring leptin were DiaSource KAP2281 Human Leptin ELISA IVD, manufactured by DIAsource ImmunoAssays S.A., Belgium. The primary outcome comprised cardiovascular death, nonfatal AMI or reinfarction, and nonfatal stroke. The co-primary outcome comprised primary events and re-hospitalization due to recurring ischemia or ischemia considered clinically significant requiring revascularization during clinical follow up. Cases of AMI were defined by criteria proposed for the universal definition of AMI^[@r32]^. Cases of stroke were defined according to World Health Organization (WHO) classical criteria^[@r33]^. The distributions of the continuous variables were expressed as mean (± standard deviation) or median (with interquartile interval), as appropriate, and the comparisons between the groups were calculated by using Student *t* test or non-parametric (Kruskall-Wallis test), as appropriate. The distributions of the categorical variables were expressed as frequencies and percentages, and the comparisons calculated by using chi-square test or Fisher exact test, as appropriate. The analysis of the primary and co-primary clinical outcomes was based on the time for the occurrence of the first event. Cox univariate regression analysis gathered all demographic, metabolic, inflammatory, anthropometric and angiographic variables, and only those univariate predictors with p \< 0.10 and variables with clinical significance were included in Cox proportional hazards regression models to determine whether adiponectin would be an independent risk predictor. Backward stepwise regression was used for the models to identify the independent variables of risk for the occurrence of primary and co-primary outcomes, respectively. Then, Firth\'s penalized likelihood method was used to adjust the potentially overestimated variables due to elevated prevalence. The results were expressed as hazard ratio and 95% confidence interval (CI), and the discriminatory capacity of the models was expressed by c-statistic (or c index). Two-tailed tests were used with significance level of α = 0.05^[@r34],[@r35]^.

Results
=======

Characteristics of the Patients
-------------------------------

[Table 1](#t01){ref-type="table"} lists the major characteristics of the 114 patients with ACS according to adiponectin quartiles. Their mean (± SD) age was 62 (± 10.5) years, 41.2% were of the female sex and 82.6%, Caucasians. The prevalence of cardiovascular risk factors was significant as follows: arterial hypertension, 90%; DM, 30%; dyslipidemia, 78%; and current tobacco use, 16.4%. The medians (interquartile interval) of the anthropometric parameters were as follows: body mass index (BMI) = 27.4 (24.6-30.4) kg / m^2^ and waist circumference = 98 (91-108) cm. Regarding electrocardiographic (ECG) findings, 97.3% of the patients had alterations, the most frequent (30.9%) being ST-segment depression between 0.5 and 1.0 mm. The final diagnosis defined 90.3% of the patients with ACS with no persistent ST-segment elevation.

###### 

Clinical characteristics according to adiponectin quartiles

  Characteristics                  Q1             Q2            Q3            Q4            P
  -------------------------------- -------------- ------------- ------------- ------------- --------
  Age                              60.6 ± 9.4     60.7 ± 9.6    64.3 ± 11.2   64.9 ± 11.8   0.29
  Female sex                       25%            31%           51.7%         57.1%         0.037
  Caucasian ethnicity              71.4%          86.2%         89.7%         85.7%         0.84
  Δt for admission, min            353 ± 45       412 ± 62      482 ± 101     330 ± 65      0.47
  Weight, kg                       81.8 ± 14.5    77.2 ± 12.8   70.5 ± 13.2   66 ± 13.5     0.0001
  BMI, kg/m^2^                     29.6 ± 5.2     28.3 ± 5.0    27.5 ± 4.4    26.4 ± 5.3    0.10
  Waist circumference, cm          105.2 ± 11.8   99.2 ± 12.8   97.1 ± 11.4   93.4 ± 12.0   0.004
  SBP, mmHg                        136 ± 22.6     137 ± 33      147 ± 22.6    142 ± 30.4    0.38
  DBP, mmHg                        81 ± 18.2      81 ± 17.3     84 ± 13.1     85 ± 16.9     0.72
  HR, bpm                          73 ± 12        76 ± 16       76 ± 15       83 ± 23       0.61
  Killip I                         96.3%          89.3%         85.2%         89.3%         0.52
  Killip II/III                    3.7%           3.6%          11.1%         10.7%         
  Killip IV                        0%             7.1%          3.7%          0%            
  Diabetes mellitus                35.7%          24.1%         31%           28.6%         0.81
  Dyslipidemia                     85.7%          72.4%         82.8%         71.4%         0.48
  Previous AMI                     60.7%          44.8%         44.8%         39.3%         0.41
  Previous PCI                     46.4%          37.9%         48.3%         42.9%         0.88
  Previous CABG                    28.6%          25%           27.6%         17.9%         0.82
  Previous stroke                  10.7%          3.4%          10.7%         3.7%          0.59
  Current smoking                  10.7%          13.8%         23.1%         18.5%         0.62
  Previous angina                  57.1%          58.6%         58.6%         46.4%         0.77
  Previous CKF                     7.1%           0%            6.9%          14.3%         0.24
  SAH                              92.9%          82.8%         96.6%         85.7%         0.30
  LVEF                             0.53           0.49          0.53          0.46          0.66
  Moderate/severe LV dysfunction   33.3%          42.3%         19.2%         30.4%         0.35

∆t: time interval; HR: heart rate; LVEF: left ventricular ejection fraction; SAH: systemic arterial hypertension; BMI: body mass index; CKF: chronic kidney failure; DBP: diastolic blood pressure; SBP: systolic blood pressure; CABG: coronary artery bypass graft surgery; LV: left ventricle.

Biomarkers in the global sample
-------------------------------

[Table 2](#t02){ref-type="table"} shows the values of biomarkers according to adiponectin quartiles. The median adiponectin level was 9,807 (6,113-13,914) ng/mL.

###### 

Biomarkers according to adiponectin quartiles

  Biomarkers                 Q1            Q2             Q3            Q4            p
  -------------------------- ------------- -------------- ------------- ------------- --------
  Leptin, ng/mL              4941 ± 4686   5471 ± 5142    7124 ± 7977   4037 ± 4592   0.41
  Insulin, µUI/mL            11.36 ± 8.6   10.28 ± 10.1   9.83 ± 5.1    7.80 ± 6.5    0.06
  Glucose, mg/dL             117 ± 42      118 ± 59       116 ± 91      110 ± 42      0.67
  HbA1c, %                   7.1 ± 1.7     6.6 ± 1.5      6.4 ± 1.12    6.4 ± 1.43    0.25
  HOMA index                 3.35 ± 3.13   2.92 ± 3.15    3.04 ± 3.31   2.23 ± 2.17   0.20
  Total cholesterol, mg/dL   182 ± 43      170 ± 37       190 ± 42      191 ± 53      0.32
  LDL-cholesterol, mg/dL     107 ± 31      104 ± 33       122 ± 40      116 ± 40      0.31
  HDL-cholesterol, mg/dL     34 ± 6        34 ± 6         41 ± 8        43 ± 11       0.0001
  Triglycerides, mg/dL       221 ± 130     174 ± 127      137 ± 57      149 ± 88      0.03
  CKMB mass, ng/mL           12.9 ± 27.4   107.9 ± 394    20.8 ± 45.3   27.1 ± 62.3   0.62
  TnI, ng/mL                 6.44 ± 12.8   36 ± 99        9.44 ± 17     13.7 ± 26.6   0.65
  us-CRP, mg/dL              6.13 ± 15.9   6.2 ± 9.96     3.14 ± 3.73   10.5 ± 21.3   0.89
  Leukocytes, /mm^3^         8689 ± 3189   8978 ± 4480    8446 ± 2921   7620 ± 2118   0.61
  Platelets, x10^3^/mm^3^    239 ± 101     218 ± 511      236 ± 606     226 ± 596     0.61
  BNP, pg/mL                 120 ± 191     163 ± 222      169 ± 252     437 ± 573     0.21
  Fibrinogen, mg/dL          392 ± 88      343 ± 86       354 ± 86      344 ± 83      0.12
  Creatinin, mg/dL           1.07 ± 0.33   1.16 ± 0.18    1.06 ± 0.28   1.24 ± 0.68   0.044

BNP: type-B natriuretic peptide; CKMB: creatine kinase, MB fraction; HbA1c: glycated hemoglobin; HOMA: Homeostasis Model Assessment; HDL: high-density lipoprotein; LDL: low-density lipoprotein; us-CRP: ultrasensitive C-reactive protein; TnI: cardiac troponin I.

Pharmacological Treatment
-------------------------

### Medications used before and during hospitalization

Previous treatments included the following drugs: acetylsalicylic acid (ASA), 69%; angiotensin-converting-enzyme inhibitors (ACEI), 62.2%; beta-blockers, 60.4%; statins, 59.8%; oral antidiabetic drugs, 13.2%; and insulin, 1.8%. No patient included was on previous use of thiazolidinediones. Regarding the drugs used during hospitalization to manage ACS, the following stand out: ASA, 99.1%; clopidogrel, 96.5%; beta-blockers, 89.5%; ACEI, 88.5%; statins, 98.2%; and low-molecular weight heparin (enoxaparin) for anticoagulation, 93.8%.

Procedures Performed during Hospitalization
-------------------------------------------

Cardiac catheterization for coronary angiography was performed in 87.7% of the patients. Luminal stenosis ≥ 50% characterized significant CAD, which was documented in at least one vessel in 83% of the patients, and in multiple arteries in 38%. Percutaneous coronary intervention was performed in 47 patients undergoing diagnostic angiography (49%), 76.6% of whom underwent implantation of one coronary stent, and 21.3%, more than one stent. Of the stents implanted, 91% were conventional (non-pharmacological). Coronary artery bypass graft surgery was performed in 15.6% of the patients, the left internal thoracic artery being used in 100% of the patients, and grafts being applied to at least three coronary arteries in two thirds of the patients.

Clinical Outcomes
-----------------

Primary outcome was observed in 18.4% of the patients, and co-primary outcome, in 21.1%, with a mean 1.13-year clinical follow-up in all 114 patients recruited. Thus, follow-up was performed in 100% of the patients, with no loss to follow-up.

Adiponectin as a Predictor of Cardiometabolic Risk
--------------------------------------------------

The Cox models included the following variables that showed significance for the association with primary and co-primary outcomes: adiponectin; other biomarkers; clinical characteristics; angiographic variables; and treatments and procedures performed before and during hospitalization. The models were calculated for four prespecified groups of interest: overall population (group A); patients with no DM (group B); patients with no ST-segment elevation AMI (group C); and patients with neither DM nor ST-segment elevation AMI (group D) ([Tables 3](#t03){ref-type="table"}-[6](#t06){ref-type="table"}). Some of the variables included in the model for primary outcome were as follows: previous angina; arterial hypertension; Killip classification; adiponectin; leptin; fasting glucose; creatinine; CKMB activity; CKMB mass; TnI; BNP; and urea. After adjusting for those factors, adiponectin was associated with high risk for the primary outcome in the models for groups B and D. For co-primary outcome, the following variables were included: previous angina; arterial hypertension; Killip classification; adiponectin; leptin; fasting glucose; creatinine; CKMB activity; heart rate (HR) on admission, HDL-cholesterol; HOMA index; obesity and in-hospital use of ASA. Adiponectin was consistently an independent predictor of high risk for cardiovascular events in the models of groups B and D, with borderline significance for group C.

###### 

Cox models for the global population (group A)

  Primary and co-primary outcomes                                                                                                                       
  ---------------------------------- ----------------- ------------------ ----------------- ------------------ ----------- ------- ----------- ------- --------
                                                                          **Coefficient**   **Hazard ratio**                       **95%CI**           **p**
  Troponin I (per 1)                                                      0.009             1.009                          1.002               1.014   0.016
  Fasting glucose (per 10)                                                0.071             1.074                          1.021               1.114   0.01
  **C indices per time intervals**                                                                                                                     
                                                                                                                                                       
  30 days                            180 days          365 days                                                                                        
  0.7208                             0.6641            0.6641                                                                                          
                                                                                                                                                       
                                     **Coefficient**   **Hazard ratio**                                        **95%CI**                               **p**
  Previous angina                    0.987             2.684                                0.955                          9.038                       0.0616
  Adiponectin (per 1,000)            0.047             1.048                                0.996                          1.093                       0.0687
  Fasting glucose (per 10)           0.054             1.055                                0.998                          1.099                       0.0562
  **C indices per time intervals**                                                                                                                     
                                                                                                                                                       
  30 days                            180 days          365 days                                                                                        
  0.6346                             0.7719            0.7719                                                                                          

###### 

Cox models after excluding patients with diabetes and ST-segment elevation AMI (group D)

  Primary and co-primary outcomes                                                                      
  ---------------------------------- ----------------- ------------------ ------- ----------- ------- -------
                                     **Coefficient**   **Hazard ratio**           **95%CI**           **p**
  Previous angina                    1.213             3.364              0.89                18.16   0.07
  Adiponectin (per 1,000)            0.077             1.080              1.02                1.13    0.012
  Troponin I (per 1)                 0.038             1.039              1.001               1.075   0.04
  **C indices per time intervals**                                                                    
                                                                                                      
  30 days                            180 days          365 days                                       
  0.7994                             0.8032            0.8032                                         
                                                                                                      
                                     **Coefficient**   **Hazard ratio**           **95%CI**           **p**
  Previous angina                    1.940             6.96               1.54                65.8    0.009
  Adiponectin (per 1,000)            0.069             1.072              1.01                1.12    0.02
  **C indices per time intervals**                                                                    
                                                                                                      
  30 days                            180 days          365 days                                       
  0.7390                             0.8199            0.8199                                         

The logistic regression analysis showed an almost linear relationship between adiponectin, as a quantitative continuous variable, and the estimate of the probability of risk for primary and co-primary outcomes ([Figure 1](#f01){ref-type="fig"}).

![Adiponectin values and risk estimation for the outcomes.](abc-101-05-0399-g01){#f01}

Correlations Between Adiponectin and Biomarkers
-----------------------------------------------

As prespecified, the secondary objective was to study the correlations between adiponectin and the different biomarkers, and demographic and anthropometric variables. [Table 7](#t07){ref-type="table"} emphasizes the direct and significant correlation between adiponectin and BNP.

###### 

Correlations between adiponectin and quantitative variables

  Variables             Correlation coefficient   p
  --------------------- ------------------------- ----------
  BNP                   0.221                     0.02
  BMI                   \- 0.239                  0.01
  Weight                \- 0.412                  \< 0.001
  Height                \- 0.346                  \< 0.001
  Waist circumference   \- 0.309                  0.001
  Age                   0.236                     0.01

BNP: type-B natriuretic peptide; BMI: body mass index.

Discussion
==========

This study of a cohort of patients with ACS on mid/long-term clinical follow-up detected a direct, significant and independent association between adiponectin and the risk for relevant cardiovascular clinical outcomes. There was consistent signaling of more evident risk when patients with DM or ST-segment elevation AMI were excluded. Cavusoglu et al^[@r29]^ have assessed 325 male patients with stable angina, unstable angina and non-ST-segment elevation AMI, who underwent coronary angiography to determine the prognostic value of serum adiponectin levels. The patients were followed up for 24 months for the occurrence of all-cause death, cardiovascular mortality and AMI. In that study, the authors have identified a direct and independent predictive association between a single baseline adiponectin measurement and the subsequent risk of death and AMI. In the subgroup of non-ST-segment elevation ACS (n = 170), adiponectin remained as an independent risk predictor. Other recent studies have also identified a direct association between adiponectin and cardiovascular risk, especially in patients with HF, mainly the elderly^[@r26]-[@r28]^. Wannamethee et al^[@r28]^have prospectively studied the relationship between adiponectin levels and mortality in 4,046 male elderly (60 79 years of age), with and without documented CVD and HF. After adjusting for important baseline characteristics, adiponectin remained directly and significantly associated with total and cardiovascular mortalities in men without CVD or HF (adjusted RR: 1.55, 95%CI: 1.19-2.02, p = 0.002; and RR: 1.53, 95%CI: 1.03 2.27, p = 0.02), for a trend in comparing the highest and the lowest tertiles, as well as in men with diagnosed HF (adjusted RR: 2.37, 95%CI: 0.64 8.79, p = 0.04; and RR: 3.43 95%CI: 0.54 21.7, p = 0.008). No association was demonstrated in those with diagnosed CVD, but no HF.

Our study has some important differences as compared with those previously discussed. Ours included patients of a wider age group, no analysis restricted only to the oldest. Similarly, this study was not restricted to the inclusion of male individuals^[@r21]-[@r23],[@r26]-[@r29]^, emphasizing that there was adequate balance in the sex proportions, with significant female representation (41.2%). In fact, the mean adiponectin level is approximately 50% greater in women, mainly elderly ones, as compared with men in the same age group^[@r13],[@r36]^. In terms of independent risk prediction, this study findings are in accordance with those of the most recent literature regarding the prognostic value of adiponectin in different clinical scenarios, either under stable conditions and in populations considered healthy or without documented CVD, or under acute clinical conditions or manifest CVD, as in the present study. Some studies have identified an independent association between adiponectin and higher risk for CAD (nonfatal AMI and fatal CAD) in individuals with no previous documentation, but only in the elderly, with adjusted OR of 1.69 (95%CI: 1.23-2.32) for the 5^th^ quintile *versus* the 1st quintile^[@r25]^. However, the Rancho Bernardo study^[@r24]^ has reported that adiponectin levels in the 5th quintile stratified by sex were significantly associated with a 44% reduction in OR for the occurrence of CAD, which was eliminated after adjusting for HDL-cholesterol and/or triglycerides. In the 20-year prospective analysis, higher concentrations of adiponectin were predictive of reduced risk for nonfatal AMI only in men. Corroborating that information, a recent study on adiponectin and risk of CAD-related events in the context of a meta-analysis of seven prospective studies has reported an OR for CAD of 0.89 (95%CI: 0.67-1.18), comparing men in the 3rd tertile with the 1st tertile, very similar to the findings of that meta-analysis^[@r22]^. Wolk et al^[@r37]^ have assessed 499 patients undergoing coronary angiography, 168 of whom with ACS, and identified that high adiponectin levels are independently associated with a reduced risk of ACS.

Of the studied correlations between adiponectin and other biomarkers, we detected a direct and significant one with BNP. Thus, possible interactions like that cannot be ruled out, among others identified and non-measurable factors or variables, which can explain the attenuation of the strength of the association with the risk in the global model. That hypothesis is supported by the study by Schnabel et al^[@r38]^, in which the association of risk and adiponectin remained robust after adjusting for classical risk factors in the global population studied. However, after adjusting for BNP, adiponectin lost its independent predictive value. Because of those findings, in patients with manifest CAD, adiponectin seems to have a different role. In clinically asymptomatic individuals, high adiponectin levels seem to protect against atherosclerotic disease; however, when elevated in patients with symptomatic CAD, a direct association with risk for cardiovascular events is observed. That result of direct or paradoxical association implies that the beneficial influence of adiponectin in atherosclerotic disease would be translated into elevations in adiponectin concentrations as a contra regulatory mechanism in response to the excessive and unstable atherosclerotic process of the ACS, with a negative net result, despite the high concentrations of that biomarker. That could indicate unbalance of the entire metabolic homeostatic system, interfering with cellular bioenergetic processes.

It is worth noting that the presence of a strong association between risk factor and the outcome assessed does not necessarily mean that the risk factor provides a base for an effective predictive rule. Wang et al^[@r39]^have shown that, in individual risk assessment, the use of ten biomarkers added only a discrete discriminatory capacity to the classical risk factors, with practically overlapping ROC curves and similar c indices (0.76 *versus* 0.77).

Finally, there is the question about the potential mechanisms of the increased risk for relevant cardiovascular events. A recent review has assessed the different pathophysiological mechanisms of adiponectin and has concluded that those associations provide relevant information to understand the inflammatory and atherogenic processes associated with CAD progression and instability of atheromatous plaques^[@r40]^. Those mechanisms include the following: 1) involvement of adiponectin in the regulation of the necrotic core development; 2) double role in the neovascularization process due to pro/antiatherogenic properties; the ability to promote angiogenesis has been proven to be beneficial to prevent ischemia; 3) the inverse relationship between adiponectin and the ratio between matrix metalloproteinases and the tissue inhibitor of metalloproteinase-1 suggests that adiponectin modulates the stability of atheromatous plaques by balancing that relationship; 4) local adiponectin in the intima and adventitia suppresses the expression of VCAM-1 and ICAM-1 adhesion molecules in vascular walls, suggesting that adiponectin improves atherosclerosis partially by inhibiting the expression of those inflammatory molecules *in vivo*. Adiponectin has a documented role in the following: endothelial activation; propagation of inflammatory factors through expression of adhesion molecules; monocyte adhesion to vascular endothelium and migration to the intima; macrophage activation; transformation of macrophages into foam cells; lipid accumulation in macrophages; proliferation and migration of smooth muscle cells to the intima; and platelet aggregation. Other mechanisms involved also include the phenomena of oxidation and vascular tone regulation.

Of the metabolic variables studied, in addition to adiponectin itself, only fasting glucose showed a significant direct and independent correlation with cardiovascular risk. Our results are comparable to those of several studies on the prognostic role of hyperglycemia on ACS, especially AMI. That might either reflect an unbalance of the systems regulated by adiponectin, as previously discussed, or be influenced by the contra-regulatory mechanisms responsible for stress hyperglycemia. However, because of the associations observed between the biomarkers, specifically with adiponectin, and little or no correlation with us-CRP, leukocytes, platelets and fibrinogen, in addition to maintenance of the association with glycemia even with the strong effect of association of CKMB mass, reflecting the impact of the myocardial necrosis grade, we think that the fasting glucose findings might actually reflect interactions with the effects of adiponectin. Similarly, the results demonstrated by adiponectin quartiles suggest and strengthen that glycemia levels are directly associated with adiponectin levels, exerting an interaction or collinearity effect.

In addition, this study performed serial measurements of neither adiponectin nor the different biomarkers of metabolism, such as glycemia, insulin, HOMA index and HbA1c. Such serial measurements could provide additional relevant information for better understanding metabolic homeostasis interrelations.

This study found a significant and direct association between adiponectin and the female sex, presence of comorbidities, chronic kidney failure, current smoking and HDL-cholesterol and creatinine levels. In addition, this study found a significant and inverse association between adiponectin and DM, body weight, waist circumference and insulin and triglyceride levels. In fact, the results between the different clinical variables and biomarkers emphasize internal consistency with those previously reported, and with similar patterns, reinforce the aspect of consistency, and indicate similar trends, suggesting that the results should be considered satisfactory and interpretable. However, as in other observational cross sectional studies, there are some limitations, such as selection biases, in addition to confounding factors not completely elucidated, and, thus, without ideal adjustment. However, we emphasize that systematic efforts were planned to minimize those aspects, as follows: consecutive recruitment of eligible patients; prospective and standardized data collection, mainly of clinical events since ACS onset and representing 100% of the patients; adjustment of Cox models for important co-variables, such as age, sex, CAD extension, other metabolic, inflammatory and myocardial necrosis biomarkers, left ventricular function, coronary revascularization procedures and pharmacological therapy with proven cardiovascular benefit. Considering the unpredictability of the variability of the different measures in the population studied, the occurrence of non-measured confounding factors, and the exploratory nature of the hypotheses, the findings and conclusions of the study should be considered as suggestive or indicative, supporting their applicability to the Brazilian population and contributing to the formulation of new hypotheses.

Conclusions
===========

The results of this study add information about the potential prognostic role of serum adiponectin levels in patients with ACS. In addition, they support the concept of metabolic homeostasis as an essential biological process that determines cardiovascular risk. Elevated total serum adiponectin levels were independent and direct predictors of the occurrence of relevant cardiovascular outcomes, such as re-hospitalization requiring revascularization. The data discussed emphasize the correlations between adiponectin and anthropometric, metabolic and myocardial biomarkers, and evoke additional investigations to determine the mechanisms involved in the following: the direct association of adiponectin with greater cardiovascular risk; the significant correlation with BNP; and the potential modulation of that biomarker as a therapeutic target.
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###### 

Cox models after excluding the diabetic patients (group B)

  Primary and co-primary outcomes                                                                      
  ---------------------------------- ----------------- ------------------ ------- ----------- ------- -------
                                     **Coefficient**   **Hazard ratio**           **95%CI**           **p**
  Troponin I (per 1)                 0.012             1.012              1.004               1.018   0.004
  Adiponectin (per 1,000)            0.076             1.079              1.018               1.13    0.014
  **C indices per time intervals**                                                                    
                                                                                                      
  30 days                            180 days          365 days                                       
  0.8314                             0.7906            0.7906                                         
                                                                                                      
                                     **Coefficient**   **Hazard ratio**           **95%CI**           **p**
  Previous angina                    1.461             4.310              1.17                22.98   0.026
  Adiponectin (per 1,000)            0.067             1.070              1.01                1.12    0.023
  **C indices per time intervals**                                                                    
                                                                                                      
  30 days                            180 days          365 days                                       
  0.6346                             0.7719            0.7719                                         

###### 

Cox models after excluding ST-segment elevation AMI (group C)

  Primary and co-primary outcomes                                                                      
  ---------------------------------- ----------------- ------------------ ------- ----------- ------- -------
                                     **Coefficient**   **Hazard ratio**           **95%CI**           **p**
  Fasting glucose (per 10)           0.078             1.081              1.03                1.12    0.005
  Adiponectin (per 1,000)            0.05              1.051              0.997               1.098   0.06
  **C indices per time intervals**                                                                    
                                                                                                      
  30 days                            180 days          365 days                                       
  0.7039                             0.7025            0.7025                                         
                                                                                                      
                                     **Coefficient**   **Hazard ratio**           **95%CI**           **P**
  Previous angina                    1.262             3.53               1.17                13.88   0.023
  Adiponectin (per 1,000)            0.050             1.051              0.998               1.096   0.05
  **C indices per time intervals**                                                                    
                                                                                                      
  30 days                            180 days          365 days                                       
  0.7368                             0.7330            0.7330                                         
